First shot at pan-coro­n­avirus vac­cine dis­ap­points in VBI Vac­cines study

The first da­ta from a clin­i­cal tri­al of a vac­cine de­signed to pro­tect against many kinds of coro­n­avirus­es sug­gest that ef­forts to sig­nif­i­cant­ly im­prove over ex­ist­ing Covid-19 shots will be ham­pered by high lev­els of im­mu­ni­ty that many peo­ple al­ready have to the virus.

The re­sults of the 101-per­son study con­duct­ed by VBI Vac­cines were dis­closed Wednes­day morn­ing in a press re­lease. The an­nounce­ment, which was light on de­tails, said that the pan-coro­n­avirus vac­cine boost­ed an­ti­bod­ies against mul­ti­ple vari­ants of SARS-CoV-2 as well as coro­n­avirus­es that in­fect bats and pan­golins.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER